Michael L. Klein, PhD

Mike Klein joins Attralus with over 30 years of experience in the biotechnology industry. He has spent his career working in various aspects of CMC development of therapeutic proteins, including 25 years with monoclonal antibodies and related proteins (Fc fusions, bispecifics, multifunctionals).

Mike most recently served as Vice President of Analytical Development at Nektar Therapeutics, serving on the leadership team of the company’s Product Development and Manufacturing group. Mike has also served as a CMC scientific leader at Agenus, Atara Bio, Xencor, Protein Design Labs, and Amgen. At Atara, Mike led the CMC function at the company’s outset, moving their Fc fusion proteins and MAbs into clinical development as the company moved from pre-IPO to public.

Mike received his Ph.D. in Biological Chemistry from UCLA and was a postdoctoral fellow in the Division of Immunology at the Beckman Research Institute of the City of Hope.